[HTML][HTML] Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y Huang, S Chen, S Wu, G Dong, C Sheng - Acta Pharmaceutica Sinica B, 2020 - Elsevier
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
[HTML][HTML] Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y Huang, S Chen, S Wu, G Dong… - … Pharmaceutica Sinica. B, 2020 - ncbi.nlm.nih.gov
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y HUANG, S CHEN, S WU, G DONG… - Acta Pharmaceutica …, 2020 - pesquisa.bvsalud.org
ABSTRACT A great challenge in multi-targeting drug discovery is to identify drug-like lead
compounds with therapeutic advantages over single target inhibitors and drug …
compounds with therapeutic advantages over single target inhibitors and drug …
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.
Y Huang, S Chen, S Wu, G Dong… - … Pharmaceutica Sinica. B, 2019 - europepmc.org
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y Huang, S Chen, S Wu, G Dong… - Acta pharmaceutica …, 2020 - pubmed.ncbi.nlm.nih.gov
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y Huang, S Chen, S Wu, G Dong, C Sheng - 2020 - hero.epa.gov
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
[HTML][HTML] Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y Huang, S Chen, S Wu, G Dong… - … Pharmaceutica Sinica. B, 2019 - scienceopen.com
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
with therapeutic advantages over single target inhibitors and drug combinations. Inspired by …
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Y HUANG, C Shuqiang, WU Shanchao… - Acta Pharmaceutica …, 2020 - pesquisa.bvsalud.org
ABSTRACT A great challenge in multi-targeting drug discovery is to identify drug-like lead
compounds with therapeutic advantages over single target inhibitors and drug …
compounds with therapeutic advantages over single target inhibitors and drug …